Cargando…

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure

Heart failure (HF) is a common complication or late-stage manifestation of various heart diseases. Numerous risk factors and underlying causes may contribute to the occurrence and progression of HF. The pathophysiological mechanisms of HF are very complicated. Despite accumulating advances in treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Qingchun, Zhou, Qing, Liu, Weitao, Wang, Yutong, Xu, Xingbo, Xu, Dingli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902509/ https://www.ncbi.nlm.nih.gov/pubmed/33644138 http://dx.doi.org/10.3389/fcvm.2021.636152

Ejemplares similares

Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage?
por: Zhou, Qing, et al.
Publicado: (2021)

Prognostic Value of Serum Galectin-3 in Chronic Heart Failure: A Meta-Analysis
por: Cheng, Zhendong, et al.
Publicado: (2022)

Machine learning models in heart failure with mildly reduced ejection fraction patients
por: Zhao, Hengli, et al.
Publicado: (2022)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
por: Li, Juexing, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
por: Cappetta, Donato, et al.
Publicado: (2021)

Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis
por: Chen, Xiehui, et al.
Publicado: (2022)

Congestive Heart Failure Exhibited Higher BMI With Lower Energy Intake and Lower Physical Activity Level: Data From the National Health and Examination Nutrition Survey
por: Xu, Tianyu, et al.
Publicado: (2021)

Triglyceride-Glucose Index and Homeostasis Model Assessment-Insulin Resistance in Young Adulthood and Risk of Incident Congestive Heart Failure in Midlife: The Coronary Artery Risk Development in Young Adults Study
por: Zeng, Xianghui, et al.
Publicado: (2022)

Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
por: Yin, Ziwei, et al.
Publicado: (2022)

Association Between Dietary Fiber Intake and Heart Failure Among Adults: National Health and Nutrition Examination Survey 2009–2018
por: Zhang, Hao, et al.
Publicado: (2022)

The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease
por: Neijenhuis, Ralph M. L., et al.
Publicado: (2023)

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
por: Mascolo, Annamaria, et al.
Publicado: (2022)

The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis
por: Lin, Yanxia, et al.
Publicado: (2022)

Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses
por: Li, Runmin, et al.
Publicado: (2023)

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Zhou, Hufang, et al.
Publicado: (2022)

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis
por: Treewaree, Sukrit, et al.
Publicado: (2023)

Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials
por: Tornyos, Dániel, et al.
Publicado: (2022)

Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021)

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy
por: Yu, Yong-Wei, et al.
Publicado: (2022)

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2023)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study
por: Lin, Tsung-Kun, et al.
Publicado: (2022)

Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
por: Kao, Ting-Wei, et al.
Publicado: (2022)

Association of Digoxin Application Approaches With Long-Term Clinical Outcomes in Rheumatic Heart Disease Patients With Heart Failure: A Retrospective Study
por: Liu, Cheng, et al.
Publicado: (2021)

Role of the Gut Microbiota in Glucose Metabolism During Heart Failure
por: Bao, Pei, et al.
Publicado: (2022)

Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
por: Li, Xuan, et al.
Publicado: (2022)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review
por: Wu, Jinchun, et al.
Publicado: (2022)

Progressive Heart Failure and Death as the Initial Manifestation of NK/T-Cell Lymphoma: A Case Report and Literature Review
por: Zhang, Ziyu, et al.
Publicado: (2021)

Triglyceride–Glucose Index and Extracellular Volume Fraction in Patients With Heart Failure
por: Yang, Shaomin, et al.
Publicado: (2021)

Triglyceride-glucose index for the detection of subclinical heart failure with preserved ejection fraction in patients with type 2 diabetes
por: Wang, Tingting, et al.
Publicado: (2023)

Editorial: Long-term perspectives in advanced heart failure therapies
por: Schoenrath, Felix, et al.
Publicado: (2023)

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
por: Joshi, Shruti S, et al.
Publicado: (2021)

Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors
por: Angelini, Gianmarco, et al.
Publicado: (2021)

Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure
por: Ding, Kun, et al.
Publicado: (2022)

Potential favorable action of sodium-glucose cotransporter-2 inhibitors on sudden cardiac death: a brief overview
por: Sato, Tatsuya, et al.
Publicado: (2023)

Risk of hypovolemia associated with sodium–glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials
por: Rong, Xi, et al.
Publicado: (2022)

Correlations between serum laminin level and severity of heart failure in patients with chronic heart failure
por: Xie, Ling, et al.
Publicado: (2023)

Is red distribution width a valid tool to predict impaired iron transport in heart failure?
por: Campodonico, Jeness, et al.
Publicado: (2023)

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p00eko230q2ha432412dgoqo65